ClinicalTrials.gg
RecruitingNCT06508983Updated Jul 10, 2026

A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients

A Phase 3 interventional study of SG301 Injection and SG301 placebo in Relapsed/Refractory Multiple Myeloma, sponsored by Hangzhou Sumgen Biotech Co., Ltd.. Recruiting at 12 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by Hangzhou Sumgen Biotech Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 448 studies in Multiple Myeloma with a site in China — 238 open to participants now, 275 under way, 47 of them phase 3. Multiple Myeloma · China.

Planned enrollment
33rd of 406
360 · median 40
Started
2024
with 46 others
Phase 3
66 of 448
24 open now
Primary completion
2027-03
later than 133 of 274 live
Registered
309th of 448
by date

Among the 448 studies in Multiple Myeloma with a site in China, this one is the 33rd largest by planned enrollment of the 406 interventional ones that give a count, is one of 47 that started in 2024, is one of 66 in phase 3, reaches primary completion later than 133 of the 274 other live ones, and was the 309th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

238 of the 448 studies in Multiple Myeloma with a site in China are open now. Recruiting first, the newest first:

233 more — sign in →

All 238 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 448 studies in Multiple Myeloma with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effects of the addition of SG301 injection to pomalidomide and dexamethasone in subjects with relapsed or refractory multiple myeloma.

Read the detailed description

This is a randomized, placebo-controlled, double-blind, multicenter phase III clinical study to compare SG301 injection in combination with pomalidomide and dexamethasone versus placebo in combination with pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma who have received at least 1 prior treatment regimen with both lenalidomide and a proteasome inhibitor and have demonstrated disease progression.

This study consists of two stages. Stage 1 is the dose exploration stage to confirm the recommended stage 2 dose of SG301 injection in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. Stage 2 is the randomized controlled stage of SG301 injection in combination with pomalidomide and dexamethasone versus placebo in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.

03

Conditions studied

  • Relapsed/Refractory Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Understand and voluntarily sign the form (ICF).
  2. Males and females aged 18-75 years (inclusive)
  3. (ECOG) Performance Status score of 0, 1 or 2
  4. Expected survival time of ≥3 months.
  5. Subjects had a documented diagnosis of multiple myeloma with evidence of .
  6. Subjects had received at least 1 prior lines of anti-myeloma therapy, which must include lenalidomide and a proteasome inhibitor (bortezomib, carfilzomib or ixazomib) given alone or in combination.
  7. Subjects must have documented evidence of PD on or after the last regimen.
  8. Adequate function of vital organs
  9. Women of (WOCBP) must agree to follow instructions for methods of for 4 weeks before the start of study treatment, for the duration of study treatment, and for 6 months after cessation of SG301 or 4 weeks after cessation of pomalidomide, whichever is longer. WOCBP must have 2 negative serum or urine pregnancy tests, one 10-14 days prior to start of study treatment and one 24 hours prior to the start of study treatment.

Exclusion criteria

Exclusion Criteria:

  1. Primary multiple myeloma defined as participants who had never achieved at least a minimal response (MR) with any treatment during the disease course.
  2. Bone independent extramedullary disease at screening.
  3. Subjects who are primary refractory to a prior CD38 monoclonal antibody therapy.
  4. Previous exposure to pomalidomide.
  5. Subject has received chemotherapy or small molecule antitumor therapy within 2 weeks or 5 pharmacokinetic half-lives of the treatment, whichever is shorter, before the first dose of study treatment;
  6. Subject has received tumor biotherapy within 4 weeks or 5 pharmacokinetic half-lives of the treatment, whichever is shorter, before the first dose of study treatment;
  7. Subject has received agents within 4 weeks or 5 pharmacokinetic half-lives of the treatment, whichever is shorter (but not less than 14 days), before the first dose of study treatment;
  8. Active , or C.
  9. Known infection.
  10. Known active tuberculosis or positive treponema pallidum antibodies.
  11. Subjects with clinical significant organ dysfunction that does not meet the study needs.
  12. Previous allogenic stem cell transplant or stem cell transplantation (ASCT) before the first dose of study treatment.
  13. Known allergy to any component of the investigational medicinal product.
  14. Any concurrent medical or psychiatric condition or disease (eg, active systemic infection, uncontrolled diabetes, acute diffuse infiltrative pulmonary disease) that is likely to interfere with the study procedures or results or that, in the opinion of the investigator, would constitute a hazard for participating in this study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
360 participants (estimated)

Study arms

  • Experimental
    SG301 Injection in combination with pomalidomide and dexamethasone

    Participants will receive SG301 Injection in combination with pomalidomide and dexamethasone. Treatment cycles have a duration of 28 days. Participants will continue to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria are met.

    Drug: SG301 Injection · Drug: pomalidomide · Drug: dexamethasone

  • Placebo comparator
    Placebo in combination with pomalidomide and dexamethasone

    Participants in Stage 2 who randomized to this arm will receive placebo in combination with pomalidomide and dexamethasone. Treatment cycles have a duration of 28 days. Participants will continue to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria are met.

    Drug: SG301 placebo · Drug: pomalidomide · Drug: dexamethasone

Interventions

  • Dosage form: solution for infusion Route of administration: intravenous Frequency: weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) thereafter.

  • DrugSG301 placebo

    Dosage form: solution for infusion Route of administration: intravenous Frequency: weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) thereafter.

  • Dosage form: capsule Route of administration: oral Dosage: 4 mg Frequency: once daily on Days 1 through 21 of each 28-day cycle.

  • Dosage form: tablets or solution for infusion Route of administration: oral or intravenous Dosage: 40 mg (participants with BMI \< 18.5 kg/m2 received 20 mg dexamethasone) Frequency: once daily on Day 1, 8, 15, 22 of each 28-day treatment cycle.

06

What researchers measure

Primary outcomes

  1. Adverse events (stage 1)

    AEs, DLTs, laboratory abnormality, Vital signs or ECG abnormalities, ECOG scores, abnormal physical examination

    Time frame: From date of first dose of study intervention through approximately 30 days after last study intervention administration, assessed up to approximately 4 years.

  2. Recommended stage 2 dose of SG301 (Stage 1)

    Recommended stage 2 dose of SG301 will be determined based on the DLTs and safety data

    Time frame: Up to approximately 6 months.

  3. Progression Free Survival (Stage 2)

    Comparison of Progression Free Survival between treatment arms (SG301/Pomalidomide/Dexamethasone vs Placebo/Pomalidomide/Dexamethasone).

    Time frame: From baseline through the end of study. Assessed every 4 weeks after randomization until C19D1, and every 8 weeks thereafter until disease progression (IMWG criteria) or death whichever occurs first, assessed up to approximately 4 years.

Secondary outcomes

  1. Pharmacokinetics (PK): AUC

    The area under the curve (AUC) of serum concentration of the drug after the administration.

    Time frame: From date of first dose of study intervention through approximately 30 days after last study intervention administration, assessed up to approximately 4 years.

  2. Pharmacokinetics (PK): Cmax

    Cmax to maximum drug concentration.

    Time frame: From date of first dose of study intervention through approximately 30 days after last study intervention administration, assessed up to approximately 4 years.

  3. Pharmacokinetics (PK):limination half-life (T1/2)

    Limination half-life (T1/2) of the drug after administration.

    Time frame: From date of first dose of study intervention through approximately 30 days after last study intervention administration, assessed up to approximately 4 years.

  4. Immunogenicity endpoints

    Anti-SG301 antibody, neutralizing antibody (to be detected only in case of the presence of anti-SG301 antibody.

    Time frame: From date of first dose of study intervention through approximately 30 days after last study intervention administration, assessed up to approximately 4 years.

  5. Overall Response Rate

    ORR (IMWG criteria): percentage of participants with stringent complete response(sCR), complete response (CR), very good partial response (VGPR), and partial response (PR) as best overall response

    Time frame: From baseline through the end of study. It is measured from the start of treatment until disease progression, death, initiation of further anti-myeloma treatment, or cut-off date, whichever occurs first, assessed up to approximately 4 years.

  6. Percentage of Participants With Very Good Partial Response (VGPR) or Better (≥VGPR Rate)

    ≥VGPR Rate (IMWG criteria): percentage of participants with stringent complete response(sCR), complete response (CR), and very good partial response (VGPR) as best overall response.

    Time frame: From baseline through the end of study. It is measured from the start of treatment until disease progression, death, initiation of further anti-myeloma treatment, or cut-off date, whichever occurs first, assessed up to approximately 4 years.

  7. Duration of Response

    Duration of response will be restricted to subjects who achieve a best objective response of PR or better.

    Time frame: From baseline through the end of study. It is measured from the time that the criteria for objective response are first met until the date of a progression event, assessed up to approximately 4 years.

  8. Overall Survival

    Overall survival is defined as the time, in months, from randomization to the date of death from any cause.

    Time frame: From baseline through the end of study, assessed up to approximately 4 years.

  9. Percentage of Participants With Minimal Residual Disease (MRD)

    MRD was assessed by next-generation sequencing in bone marrow samples from participants who achieved CR or sCR, to determine the depth of response at the molecular level.

    Time frame: From baseline through the end of study. It is measured from the time that the criteria for CR are first met until the date of a progression event, assessed up to approximately 4 years.

07

Study locations

9 of 12 sites recruiting
  • Beijing Chaoyang Hospital of Capital Medical University
    Beijing, Beijing Municipality 100024, China
    Recruiting
    • Wenming Chen, Doctor · Contact
    • Ying Tian · Contact
  • Guangzhou First People's Hospital
    Guangzhou, Guangdong 510000, China
    Not yet recruiting
    • Shunqing Wang · Contact
    • Wei Zhou · Contact
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510000, China
    Not yet recruiting
    • Zhongjun Xia · Contact
    • Xiaoqin Chen · Contact
  • First Affiliated Hospital of Henan University of Science and Technology
    Luoyang, Henan 471000, China
    Recruiting
    • Haiping Yang · Contact
    • Bingke Zhu · Contact
  • Henan Cancer Hospital
    Zhengzhou, Henan 450000, China
    Recruiting
    • Baijun Fang · Contact
    • Yuzhang Liu · Contact
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430000, China
    Recruiting
    • Chunyan Sun · Contact
    • Fei Zhao · Contact
  • The First Affiliated Hospital Of Soochow University
    Suzhou, Jiangsu 215006, China
    Recruiting
    • ZhengZheng Fu · Contact
    • Yingying Zhai · Contact
  • Shanxi Provincial Hospital
    Taiyuan, Shanxi 030000, China
    Recruiting
    • Liping Su · Contact
    • Jingrong Wang · Contact
  • The Second Affiliated Hospital Of Xi an Jiaotong University (Xibei Hospital)
    Xi’an, Shanxi 710000, China
    Recruiting
    • Wanhong Zhao · Contact
    • Fangxia Wang · Contact
  • Tianjin Cancer University Airport Hospital
    Tianjin, Tianjin Municipality 300060, China
    Recruiting
    • Yafei Wang · Contact
    • Zhiying Zhang · Contact
  • Tianjin Medical University Cancer Institute & Hospital
    Tianjin, Tianjin Municipality 300060, China
    Not yet recruiting
    • Yafei Wang · Contact
    • Haifeng Zhao · Contact
  • The Second Affiliated Hospital Zhejiang University School Of Medicine
    Hangzhou, Zhejiang 310056, China
    Recruiting
    • Wenbin Qian · Contact
    • Xuzhao Zhang · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Mar 2027, 33 months after the start.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's planned 33 months is below that.

Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2024
First posted
Jul 19, 2024
StartActual
Jun 14, 2024
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2028
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06508983
Responsible party
Sponsor
First posted
Jul 19, 2024
Start date
Jun 14, 2024
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Jul 10, 2026

Study contacts

Jing Yang
Contact
yangjing@sumgenbio.com
+86 010-56315401

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sanritatug

Start the discussion